2025 Assessment Sessions for In Vitro Diagnostics
IVD
The In Vitro Diagnostics Assessment Team has established a new assessment model combining assessment sessions and between-assessment session work.
First tafenoquine products prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Cadila’s dispersible isoniazid tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Cadila’s dispersible ethambutol tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list :
First dispersible rifapentine tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Active Pharmaceutical Ingredient (API) Prequalified
M
Lamivudine (WHOAPI-428) manufactured by Styrax Life Sciences Pvt Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes: Extension of WHO GTB recommendation-based procurement eligibility for TB NAT assays until 31 December 2025
IVD
The World Health Organization (WHO), through its Prequalification Unit and Global Tuberculosis Programme, would like to announce that the transition period for WHO procurement el
Active Pharmaceutical Ingredient (API) Prequalified
M
Rifampicin (WHOAPI-507) manufactured by Macleods Pharmaceuticals Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.